Evidence map›Paper›PMID 42387215›Full record

ArticleNature medicine2026

Innate immune responsiveness predicts enhanced cellular immunity and symptomatic disease after controlled human influenza infection.

Loukas Papargyris, Jiayun Xu, Claire Broderick, Ao Huang, Trupti Gore, Arnold Reynaldi, Pete Dayananda, Ashley M Collins, Stephanie Ascough, Nathan Wong and 25 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors.

Loukas PapargyrisDepartment of Infectious Disease, Imperial College London, London, UK.ORCID http://orcid.org/0000-0002-5803-5826
Jiayun XuDepartment of Infectious Disease, Imperial College London, London, UK.
Claire BroderickDepartment of Infectious Disease, Imperial College London, London, UK.ORCID http://orcid.org/0000-0003-2582-4527
Ao HuangCenter for Systems and Engineering Immunology (CSEI) and Department of Immunobiology, Yale University, New Haven, CT, USA.
Trupti GoreDivision of Infection and Immunity, University College London, London, UK.ORCID http://orcid.org/0000-0001-7302-0860
Arnold ReynaldiKirby Institute, University of New South Wales, Kensington, New South Wales, Australia.ORCID http://orcid.org/0000-0002-5529-5542
Pete DayanandaDepartment of Infectious Disease, Imperial College London, London, UK.
Ashley M CollinsDepartment of Infectious Disease, Imperial College London, London, UK.
Stephanie AscoughDepartment of Infectious Disease, Imperial College London, London, UK.
Nathan WongDepartment of Infectious Disease, Imperial College London, London, UK.
Jon GuyDepartment of Infectious Disease, Imperial College London, London, UK.
Jihye SongDepartment of Infectious Disease, Imperial College London, London, UK.
Satwik KarDepartment of Infectious Disease, Imperial College London, London, UK.
Emma BergstromDepartment of Infectious Disease, Imperial College London, London, UK.
Lydia SlaterDepartment of Infectious Disease, Imperial College London, London, UK.
Zoe GardenerDepartment of Infectious Disease, Imperial College London, London, UK.
Suzanna PatersonDepartment of Infectious Disease, Imperial College London, London, UK.
Mahdi Moradi MarjanehDepartment of Infectious Disease, Imperial College London, London, UK.ORCID http://orcid.org/0000-0002-9412-9029
Samuel J NicholsDepartment of Infectious Disease, Imperial College London, London, UK.ORCID http://orcid.org/0000-0001-6737-0610
Victoria J WrightDepartment of Infectious Disease, Imperial College London, London, UK.ORCID http://orcid.org/0000-0001-7826-1516
Min Kyu ParkDepartment of Infectious Disease, Imperial College London, London, UK.
Richard McKendryDepartment of Infectious Disease, Imperial College London, London, UK.
Brad NicholsonDepartment of Medicine, Duke University School of Medicine, Durham, NC, USA.ORCID http://orcid.org/0000-0001-9517-3876
Micah McClainDepartment of Medicine, Duke University School of Medicine, Durham, NC, USA.ORCID http://orcid.org/0000-0001-8034-1136
Thomas W BurkeDepartment of Medicine, Duke University School of Medicine, Durham, NC, USA.ORCID http://orcid.org/0000-0003-0592-5822
Helen WagstaffeDepartment of Infectious Disease, Imperial College London, London, UK.ORCID http://orcid.org/0000-0002-4462-7484
Jelle KleinSGS Clinical Pharmacology Unit, Edegem, Belgium.
Michael LevinDepartment of Infectious Disease, Imperial College London, London, UK.ORCID http://orcid.org/0000-0003-2767-6919
Alba GrifoniCenter for Vaccine Innovation, La Jolla Institute for Immunology (LJI), La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-2209-5966
Christopher W WoodsDepartment of Medicine, Duke University School of Medicine, Durham, NC, USA.ORCID http://orcid.org/0000-0001-7240-2453
Miles P DavenportKirby Institute, University of New South Wales, Kensington, New South Wales, Australia.ORCID http://orcid.org/0000-0002-4751-1831
John S TsangCenter for Systems and Engineering Immunology (CSEI) and Department of Immunobiology, Yale University, New Haven, CT, USA.ORCID http://orcid.org/0000-0003-3186-3047
Benny ChainDivision of Infection and Immunity, University College London, London, UK.ORCID http://orcid.org/0000-0002-7417-3970
Myrsini KaforouDepartment of Infectious Disease, Imperial College London, London, UK.ORCID http://orcid.org/0000-0001-9878-4007
Christopher ChiuDepartment of Infectious Disease, Imperial College London, London, UK. c.chiu@imperial.ac.uk.ORCID http://orcid.org/0000-0003-0914-920X

Funding

Subjects and Samples CoreP01AI179570 · NIAID · YALE UNIVERSITY · PI Carrie L. Lucas, John S Tsang · 2025 to 2026
$9.1M
Drivers of individual variation in influenza vaccine response and protection from infectionR01AI170116 · NIAID · UNIVERSITY OF CHICAGO · PI Sarah Cobey, John S Tsang · 2022 to 2026
$7.2M
NIAID NIH HHS P01 AI179570NIAID NIH HHS R01 AI170116NIH HHS HHSN272201400008C
6 · The paper itself

Abstract

Controlled human influenza infection studies can uniquely interrogate the early immune factors associated with clinical outcome. In this study, 27 healthy volunteers with low strain-specific serum neutralizing antibody levels were challenged with influenza A/H3N2 virus. Twenty-two became infected, with 18 developing mild-to-moderate symptoms and four remaining asymptomatic. Local and systemic immune profiling revealed innate pathways that engaged more rapidly and to a higher level in symptomatic participants. Earlier monocyte and dendritic cell activation correlated with higher symptom scores but also enhanced natural killer and CD8

Indexed as

Immunity, CellularImmunity, InnateInfluenza A Virus, H3N2 SubtypeInfluenza, HumanAdultAntibodies, NeutralizingAntibodies, ViralCD8-Positive T-LymphocytesDendritic CellsFemaleHuman Challenge Trials as TopicHumansKiller Cells, NaturalLeukocytes, MononuclearLymphocyte ActivationMaleAntibodies, NeutralizingAntibodies, Viral

Identifiers

PMID42387215
PMCPMC13375583

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.